Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | FDPS | P14324 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7246721 | 1.00 | ACHE (0.43) | ACHECHRNB2CHRNA4CHRNA7FDPS | |
| SCHEMBL29422947 | 1.00 | ACHE (0.43) | ACHECHRNB2CHRNA4CHRNA7FDPS | |
| SCHEMBL7246720 | 1.00 | ACHE (0.43) | ACHECHRNB2CHRNA4CHRNA7FDPS | |
| SCHEMBL7240759 | 0.88 | ACHE (0.46) | ACHE | |
| SCHEMBL7240762 | 0.88 | ACHE (0.46) | ACHE | |
| SCHEMBL7240765 | 0.88 | ACHE (0.46) | ACHE | |
| SCHEMBL3819190 | 0.86 | CHRNB2 (0.38) | ACHECHRNB2CHRNA4CHRNA7 | |
| Hydrochloric Acid SCHEMBL52345 | 0.85 | CHRNB2 (0.37) | ACHECHRNB2CHRNA4CHRNA7 | |
| Hydrochloric Acid SCHEMBL3134497 | 0.85 | CHRNB2 (0.37) | ACHECHRNB2CHRNA4CHRNA7 | |
| SCHEMBL4541235 | 0.75 | ACHE (0.39) | ACHECHRNB2CHRNA4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210145818-A1 | COMPOSITIONS INFUSED WITH NICOTINE COMPOUNDS AND METHODS OF USE THEREOF | Poviva Corp. | 2021-05-20 | — | — | US | claimed |
| EP-3781163-A1 | COMPOSITIONS INFUSED WITH NICOTINE COMPOUNDS AND METHODS OF USE THEREOF | Poviva Corp. (US) | 2021-02-24 | — | — | EP | claimed |
| WO-2019202396-A1 | COMPOSITIONS INFUSED WITH NICOTINE COMPOUNDS AND METHODS OF USE THEREOF | POVIVA TEA, LLC (US) | 2019-10-24 | — | — | WO | claimed |
| US-10080747-B2 | Nicotinic attenuation of CNS inflammation and autoimmunity | DIGNITY HEALTH (US) | 2018-09-25 | — | — | US | claimed |
| US-9566273-B2 | Nicotinic attenuation of CNS inflammation and autoimmunity | DIGNITY HEALTH (US) | 2017-02-14 | — | — | US | claimed |
| US-20230094827-A1 | NANOEMULSION COMPOSITIONS COMPRISING BIOLOGICALLY ACTIVE INGREDIENTS | POVIVA CORP | 2023-03-30 | — | — | US | disclosed |
| US-20220160731-A1 | COMPOSITIONS COMPRISING BIOLOGICALLY ACTIVE AGENTS AND BILE SALTS | POVIVA CORP | 2022-05-26 | — | — | US | disclosed |
| EP-3972584-A1 | NANOEMULSION COMPOSITIONS COMPRISING BIOLOGICALLY ACTIVE INGREDIENTS | Poviva Corp. (US) | 2022-03-30 | — | — | EP | disclosed |
| EP-3972582-A1 | COMPOSITIONS COMPRISING BIOLOGICALLY ACTIVE AGENTS AND BILE SALTS | Poviva Corp. (US) | 2022-03-30 | — | — | EP | disclosed |
| US-20210145841-A1 | ENHANCEMENT OF DELIVERY OF LIPOPHILIC ACTIVE AGENTS ACROSS THE BLOOD-BRAIN BARRIER AND METHODS FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS | Poviva Corp. | 2021-05-20 | — | — | US | disclosed |
| US-20210145818-A1 | COMPOSITIONS INFUSED WITH NICOTINE COMPOUNDS AND METHODS OF USE THEREOF | Poviva Corp. | 2021-05-20 | — | — | US | disclosed |
| US-20210145036-A1 | LIPOPHILIC ACTIVE AGENT INFUSED COMPOSITIONS WITH REDUCED FOOD EFFECT | Poviva Corp. | 2021-05-20 | — | — | US | disclosed |
| EP-3781163-A1 | COMPOSITIONS INFUSED WITH NICOTINE COMPOUNDS AND METHODS OF USE THEREOF | Poviva Corp. (US) | 2021-02-24 | — | — | EP | disclosed |
| WO-2020236798-A1 | NANOEMULSION COMPOSITIONS COMPRISING BIOLOGICALLY ACTIVE INGREDIENTS | Poviva Corp. (US) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020236802-A1 | COMPOSITIONS COMPRISING BIOLOGICALLY ACTIVE AGENTS AND BILE SALTS | Poviva Corp. (US) | 2020-11-26 | — | — | WO | disclosed |
| WO-2019202396-A1 | COMPOSITIONS INFUSED WITH NICOTINE COMPOUNDS AND METHODS OF USE THEREOF | POVIVA TEA, LLC (US) | 2019-10-24 | — | — | WO | disclosed |
| WO-2019204502-A1 | LIPOPHILIC ACTIVE AGENT INFUSED COMPOSITIONS WITH REDUCED FOOD EFFECT | POVIVA TEA, LLC (US) | 2019-10-24 | — | — | WO | disclosed |
| US-20150238640-A1 | METHOD FOR PREPARING A MARKED PURINE DERIVATIVE, SAID DERIVATIVE AND USES THEREOF | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2015-08-27 | — | — | US | disclosed |
| US-6503922-B2 | Central nervous system (CNS); bridged nicotine analogs of N-octylnicotinium iodide (NONI) having selective antagonist properties at alpha 3 beta 2-containing nicotinic receptor subtypes | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2003-01-07 | — | — | US | disclosed |
| US-20020099069-A1 | Bridged nicotine compounds for use in the treatment of CNS pathologies | KENTUCKY RESEARCH FOUNDATION, UNIVERSITY OF | 2002-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099069-A1 | Bridged nicotine compounds for use in the treatment of CNS pathologies | CHRNB2, CHRNA5, CHRNA2 | ACHE 94/4885CHRNB2 1/4885CHRNA4 10/4885 |
| US-20210145036-A1 | LIPOPHILIC ACTIVE AGENT INFUSED COMPOSITIONS WITH REDUCED FOOD EFFECT | LIPC, PNLIP, LIPA | ACHE 1419/4885CHRNB2 4527/4885CHRNA4 4395/4885 |
| US-20210145818-A1 | COMPOSITIONS INFUSED WITH NICOTINE COMPOUNDS AND METHODS OF USE THEREOF | CHRNA5, SLC18A3, CHRNA6 | ACHE 20/4885CHRNB2 8/4885CHRNA4 9/4885 |
| US-20210145841-A1 | ENHANCEMENT OF DELIVERY OF LIPOPHILIC ACTIVE AGENTS ACROSS THE BLOOD-BRAIN BARRIER AND METHODS FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS | FABP7, LIPA, LIPC | ACHE 4/4885CHRNB2 381/4885CHRNA4 636/4885 |
| US-20150238640-A1 | METHOD FOR PREPARING A MARKED PURINE DERIVATIVE, SAID DERIVATIVE AND USES THEREOF | TPMT, NUDT1, DUT | ACHE 3717/4885CHRNB2 4367/4885CHRNA4 3945/4885 |
| US-20220160731-A1 | COMPOSITIONS COMPRISING BIOLOGICALLY ACTIVE AGENTS AND BILE SALTS | SLC10A2, ABCB11, SLC10A1 | ACHE 873/4885CHRNB2 3555/4885CHRNA4 4664/4885 |
| US-20230094827-A1 | NANOEMULSION COMPOSITIONS COMPRISING BIOLOGICALLY ACTIVE INGREDIENTS | PNLIP, LIPA, SGMS2 | ACHE 279/4885CHRNB2 2696/4885CHRNA4 3923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.